RE:RE:RE:Buyouts - USD or CADPlantrader ... The best way for you to understand biotechs market valuations on takeovers or on jv is to look to different news.
Ballpark estimates, based on what we often see for disruptive technologies:
- If TLT was only a one-indication biotech that was to become the SOC for NMIBC, it would be
acquired for approx. 3B$US, given the size of the NMIBC market and assuming 284M fully diluted shares.
- If TLT was to be successful in both NMIBC, (FDA approval) and GBM (Ph. 1b) and NSCLC (Ph. 1b) plus a portfolio of PDCs, it would be
acquired for approx. 12B$US
+, , assuming 284M fully diluted shares, considering the demonstration that PDT delivers on more than one type of indications, on complex ones, in late-stage ones and in more than one field of specilaties (urology, neurology, pulmonary).
- In the meantime, a
jv with a big pharma on NMIBC would bring us easily above the 500M$US with a FDA Breakthough Therapy designation and around 1.5B$US+ with an Accelerated Approval. Breakthrough Therapy would require us to complete the Ph. 2 before collecting revenues as Accelerated Approval would allow us to collect revenues immediately and would, for sure, attract a big pharma for a jv right.
Since 2016, TLT's plan has always been to jv on its first indication and then confirm efficacy on a Ph. 1b for the next 2 indications in order to demonstrate to full potential of the PDT#PDC technology before being acquired by selling with it, its PDC portfolio, so the acquirer can bring more indications under the PDT/PDC. That's exactly the plan TLT is executing, and it has been outlined once again in the Jan. 3rd article.
A jv for NMIBC rights would bring us upfront payments that could finance GBM and NSCLC Ph. 1b trials.
____________
plantrader - (1/17/2023 4:58:26 PM)
RE:RE:Buyouts - USD or CAD
N0taP00p wrote:Theralase uses USD for their $1.1B to $1.7B revenue opportunity projections. So I'm guessing we're all using USD.
$3B USD would be juicyyyyyyyy